On October 5, 2026, Vaxcyte Inc. sent biotech stocks soaring. Its shares jumped 31 percent, closing at $90.75—a new 52-week high. The reason: Vaxcyte released positive topline results from the Phase 3 OPUS-1 trial for its lead vaccine, VAX-31. This vaccine targets invasive pneumococcal disease and pneumonia. The study hit every primary immunogenicity goal. Vaxcyte moved fast. It launched a $500 million public offering of common stock and pre-funded warrants right after the news.
An official company press release gave more details. OPUS-1 was a randomized, double-blind, active-controlled trial. It enrolled 3,572 healthy adults aged 50 and up who had never received a pneumococcal vaccine. Another 475 people joined from the 18–49 age group. VAX-31 is a 31-valent pneumococcal conjugate vaccine. The OPUS program also includes ongoing Phase 2 dose-finding studies in infants.
VAX-31 achieved its pre-specified primary immunological objectives across all studied age groups, with a safety profile comparable to Prevnar 20 and Capvaxive.
The rally didn’t stop with Vaxcyte. Illumina Inc. and Charles River Laboratories International Inc. each gained 7 percent. Illumina closed at $296.25. Charles River Laboratories finished at $312.26. Both set new 52-week highs. Illumina’s second quarter revenue rose 9.5 percent year-over-year to $1.59 billion. The company expects full-year revenue between $4.60 billion and $4.64 billion. Demand for its DNA sequencing and genomics tools remains strong. Charles River Laboratories saw a 2.7 percent drop in quarterly revenue, landing just above $1 billion. Still, it remains a key supplier for pre-clinical drug development. In 2025, over 90 percent of FDA-approved drugs used its transgenic rodents. The company is also growing its cell-line manufacturing and toxicology testing business.
The company's public offering announcement revealed more. Vaxcyte also launched a $500 million offering of convertible senior notes due 2032. The money will fund clinical development for both adult and pediatric VAX-31 programs. Vaxcyte said OPUS-1 results will form the basis for a future Biologics License Application (BLA) to the FDA. Approval will depend on a full data package and regulatory review.
InfuSystem Holdings Inc. joined the surge. Its shares touched $13.85 after a 2 percent rise. The company reported second quarter revenue of $36.9 million, up 2.6 percent from last year. It expects full-year pro-forma net revenue growth between 6 and 8 percent. InfuSystem’s business covers electronic and ambulatory infusion pumps, biomedical device servicing, chemotherapy equipment, and wound care kits. It’s a steady player in outpatient healthcare.
OPUS-1 is a key part of Vaxcyte's registration strategy: while the company views these results as the basis for a future BLA filing, FDA approval is not guaranteed and will depend on comprehensive data and regulatory review.
HeartFlow Inc. also broke out. Its stock climbed over 5 percent to $53.07. HeartFlow specializes in AI-powered coronary artery disease diagnostics. Second quarter revenue jumped 48 percent to $64.1 million. Net losses widened to $15.7 million. HeartFlow’s non-invasive coronary CT angiography and 3D modeling tools are gaining ground for plaque analysis and planning procedures. Profitability remains a challenge.
What the numbers mean for biotech investors
Each company hit new highs for a reason. Some had strong clinical trial results. Others posted revenue growth or saw more customers adopt their products. Vaxcyte’s Phase 3 data for VAX-31 stands out as the most immediate clinical win. Illumina and Charles River Laboratories show the staying power of genomics and pre-clinical research. InfuSystem and HeartFlow, while less flashy, prove that steady gains and new technology can still move the market.
October 5, 1787, marks the day Dr. Caspar Wistar and Timothy Matlack reported the first dinosaur bone in the United States. It started with one find. Science moves forward on hard evidence. Today’s biotech rally is built the same way—on data, clear results, and proof that the work delivers. The market isn’t just guessing. It’s reacting to real progress. For investors, the lesson is simple. In biotech, proof wins. The companies that show it take the lead.
